Published in Neuro Oncol on December 01, 2009
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2014) 1.48
PET Imaging of Integrin αVβ3 Expression. Theranostics (2011) 1.41
Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol (2011) 1.40
Molecular ultrasound assessment of tumor angiogenesis. Angiogenesis (2010) 1.26
Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging (2010) 1.15
Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. Eur Radiol (2012) 1.09
Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer (2011) 1.06
Molecular imaging and targeted therapies. Biochem Pharmacol (2010) 1.05
Imaging key biomarkers of tumor angiogenesis. Theranostics (2012) 1.03
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3. Theranostics (2016) 1.02
Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials (2012) 1.02
Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. Br J Radiol (2011) 1.00
PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. Biomed Res Int (2014) 0.98
Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe. Ann Surg Oncol (2014) 0.92
PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. Cancer Res (2010) 0.92
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues. Bioconjug Chem (2014) 0.87
Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging. Bioorg Med Chem Lett (2010) 0.87
Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies. Br J Cancer (2010) 0.86
Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma. Proc Natl Acad Sci U S A (2013) 0.86
Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol Imaging Biol (2012) 0.85
A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients. Eur J Nucl Med Mol Imaging (2015) 0.85
[¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins. Eur J Nucl Med Mol Imaging (2014) 0.84
The development, past achievements, and future directions of brain PET. J Cereb Blood Flow Metab (2012) 0.84
(68)Ga-PRGD2 PET/CT in the evaluation of Glioma: a prospective study. Mol Pharm (2014) 0.82
Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Res (2015) 0.82
Glioblastomas Require Integrin αvβ3/PAK4 Signaling to Escape Senescence. Cancer Res (2015) 0.80
Clinical applications in molecular imaging. Pediatr Radiol (2010) 0.80
Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp Ther Med (2010) 0.78
alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment. Theranostics (2015) 0.78
Impairment of the cell-to-matrix adhesion and cytotoxicity induced by the Mediterranean jellyfish Pelagia noctiluca venom and its fractions in cultured glioblastoma cells. Lipids Health Dis (2012) 0.78
Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nat Rev Clin Oncol (2016) 0.77
RGD-Targeted Ultrasound Contrast Agent for Longitudinal Assessment of Hep-2 Tumor Angiogenesis In Vivo. PLoS One (2016) 0.77
Nanoparticle-facilitated functional and molecular imaging for the early detection of cancer. Front Mol Biosci (2014) 0.77
Crossing the barrier: treatment of brain tumors using nanochain particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.76
Targeted therapy for glioma using cyclic RGD-entrapped polyionic complex nanomicelles. Int J Nanomedicine (2012) 0.76
Emerging methods for disease monitoring in malignant gliomas. CNS Oncol (2013) 0.75
Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: An in vitro boron neutron capture therapy study. Oncotarget (2017) 0.75
Cellular density effect on RGD ligand internalization in glioblastoma for MRI application. PLoS One (2013) 0.75
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget (2016) 0.75
[(18)F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma. Eur J Nucl Med Mol Imaging (2015) 0.75
One-pot synthesis of nanochain particles for targeting brain tumors. Nanoscale (2017) 0.75
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem (1987) 4.87
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med (1999) 3.20
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med (2005) 3.12
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 2.93
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem (1999) 2.76
Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery (2001) 2.30
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem (2004) 2.20
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res (2006) 1.96
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med (2005) 1.94
Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des (2006) 1.88
Positron emission tomography as an imaging biomarker. J Clin Oncol (2006) 1.84
Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets (2003) 1.70
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer (2007) 1.67
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem (2006) 1.64
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs (2008) 1.56
Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol (2001) 1.48
[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 1.45
Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med (2007) 1.36
Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol (2008) 1.28
Intraoperative MR-guided neurosurgery. J Magn Reson Imaging (2008) 1.14
Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol (2001) 1.06
Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma. Anticancer Res (2001) 0.85
Chemotherapy for low-grade gliomas: emerging consensus on its benefits. Neurology (2007) 0.84
[Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination]. Nuklearmedizin (2002) 0.78
Quantification of [18F]diprenorphine kinetics in the human brain with compartmental and non-compartmental modeling approaches. Neuroimage (2004) 0.78
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science (2013) 6.34
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials (2003) 5.34
Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery (2008) 5.03
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Activation of integrin function by nanopatterned adhesive interfaces. Chemphyschem (2004) 4.66
A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain (2009) 4.40
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol (2007) 4.03
Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA (2006) 3.78
Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA (2005) 3.67
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 3.63
Cell spreading and focal adhesion dynamics are regulated by spacing of integrin ligands. Biophys J (2007) 3.57
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med (2005) 3.12
Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med (2011) 2.98
TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol (2007) 2.97
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ (2003) 2.87
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol (2009) 2.76
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med (2012) 2.76
Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol (2009) 2.68
A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol (2004) 2.67
Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med (2009) 2.65
Genetic prion disease: the EUROCJD experience. Hum Genet (2005) 2.64
Association of ST-elevation and non-ST-elevation presentation on ECG with transmurality and size of myocardial infarction as assessed by contrast-enhanced magnetic resonance imaging. J Electrocardiol (2013) 2.64
Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol (2005) 2.54
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47
Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation (2002) 2.43
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol (2003) 2.35
SPECT/CT. J Nucl Med (2008) 2.34
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol (2006) 2.31
Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med (2006) 2.23
5-Aminolevulinic acid-derived tumor fluorescence: the diagnostic accuracy of visible fluorescence qualities as corroborated by spectrometry and histology and postoperative imaging. Neurosurgery (2014) 2.23
Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging (2007) 2.23
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol (2004) 2.22
Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med (2008) 2.22
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem (2004) 2.20
ALDH1A1 is a marker of astrocytic differentiation during brain development and correlates with better survival in glioblastoma patients. Brain Pathol (2012) 2.14
Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med (2004) 2.14
First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. Eur J Nucl Med Mol Imaging (2010) 2.07
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med (2005) 2.05
TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol (2008) 2.02
N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res (2008) 2.02
TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol (2007) 2.02
Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci (2006) 1.99
Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation (2003) 1.97
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res (2006) 1.96
Positron detection for the intraoperative localisation of cancer deposits. Eur J Nucl Med Mol Imaging (2007) 1.95
Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov (2008) 1.95
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med (2005) 1.94
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem (2006) 1.94
Lateral spacing of integrin ligands influences cell spreading and focal adhesion assembly. Eur J Cell Biol (2005) 1.93
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep (2002) 1.91
TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell (2009) 1.90
Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke (2002) 1.88
FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging (2002) 1.87
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87
Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry (2009) 1.85
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med (2005) 1.85
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol (2003) 1.84
Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol (2013) 1.82
The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J Cell Biol (2007) 1.81
The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J (2011) 1.80
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology (2007) 1.79
Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol (2008) 1.78
Central poststroke pain and reduced opioid receptor binding within pain processing circuitries: a [11C]diprenorphine PET study. Pain (2004) 1.77
FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain (2011) 1.76
Impact of order and disorder in RGD nanopatterns on cell adhesion. Nano Lett (2009) 1.75
Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol (2004) 1.74
Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol (2007) 1.69
Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry (2003) 1.69
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation (2009) 1.69